ZyVersa Therapeutics, Inc. (ZVSA)
NASDAQ: ZVSA · Real-Time Price · USD
2.270
-0.160 (-6.58%)
Sep 19, 2024, 4:00 PM EDT - Market closed
ZyVersa Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -21.83 | -98.3 | -14.12 | -8.08 | -12.68 |
| Depreciation & Amortization | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Amortization | - | - | 0.04 | 0.32 | 0.29 |
| Asset Writedown & Restructuring Costs | 12.16 | 93.33 | - | - | - |
| Stock-Based Compensation | 0.92 | 1.19 | 3.58 | 4.14 | 3.68 |
| Other Operating Activities | -0.4 | -7.56 | -0.05 | -0.44 | 0.49 |
| Change in Accounts Payable | 0.17 | 2.41 | 4.54 | -0.31 | -0.6 |
| Change in Other Net Operating Assets | -0.46 | 0.19 | 1.12 | -0.71 | 3.71 |
| Operating Cash Flow | -9.41 | -8.72 | -4.89 | -5.08 | -5.11 |
| Long-Term Debt Issued | - | - | - | 5.23 | 1.69 |
| Net Debt Issued (Repaid) | - | - | - | 5.23 | 1.69 |
| Issuance of Common Stock | 10.74 | 19.08 | - | - | 3.02 |
| Repurchase of Common Stock | - | -0.01 | - | - | - |
| Other Financing Activities | -1.2 | -2.42 | -0.1 | - | -0.14 |
| Financing Cash Flow | 9.31 | 5.96 | 1.87 | 5.23 | 4.56 |
| Net Cash Flow | -0.11 | -2.76 | -3.02 | 0.15 | -0.55 |
| Free Cash Flow | -9.41 | -8.72 | -4.89 | -5.08 | -5.11 |
| Free Cash Flow Per Share | -21.26 | -89.44 | -74.56 | -2.10 | -75.66 |
| Levered Free Cash Flow | -5.54 | -5.46 | -1.65 | -2.02 | - |
| Unlevered Free Cash Flow | -5.54 | -5.46 | -1.43 | -1.83 | - |
| Change in Net Working Capital | 0.07 | -2.35 | -3.63 | 1.27 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.